Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Jun 04, 2023 6:34pm

180 Views

Post# 35479491

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

That fourth slide is very interesting.

Though barely legible, this is my take:

1. The data is an update as of May 2023. A great relief, I must say.

2. Pela/Pax Median PFS 9.6 months (It looks like 9.6), versus... And this is the big reveal...

3. Pax stand alone PFS 4.4 months (It looks like 4.4).

So, more than double median PFS.

Gosh, I hope that Pax number is 4.4. This is a homerun IMO (with the support of IND.213).

Disregard my previous post, I'm in a much better mood now. Looking forward to Monday morning.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Sept. 20, 2024)